eCARTv5 Clinical Deterioration Suite (eCART) vs Google Med-PaLM 2
AI Verdict
Choose eCARTv5 Clinical Deterioration Suite (eCART) if…
Choose eCARTv5 Clinical Deterioration Suite if your primary goal is to proactively identify and manage the risk of clinical deterioration in hospitalized adult patients. This FDA-cleared, AI-powered Software as a Medical Device continuously assesses patient data from EHRs to predict critical events like death or ICU transfer hours before they occur, guiding care with embedded clinical pathways. It's ideal for hospitals seeking to reduce adverse outcomes, minimize false alarms, and improve overall patient safety and care efficiency on medical-surgical wards.
View eCARTv5 Clinical Deterioration Suite (eCART) →Choose Google Med-PaLM 2 if…
Choose Google Med-PaLM 2 if your organization requires an advanced large language model specifically fine-tuned for a broad range of healthcare applications, including complex clinical decision support, medical summarization, and in-depth medical Q&A. This tool excels at expert-level medical reasoning, synthesizing medical literature, and analyzing multimodal data like medical images and patient histories. It is best suited for institutions looking to enhance diagnostic accuracy, support medical education, accelerate research, or develop personalized treatment recommendations.
View Google Med-PaLM 2 →Quick Comparison
| Feature | eCARTv5 Clinical Deterioration Suite (eCART) | Google Med-PaLM 2 |
|---|---|---|
| Pricing | Contact vendor for tailored quote. | Contact for pricing |
| Deployment | Cloud-based SaaS, integrated directly into Electronic Health Record (EHR) systems. | Cloud-based (Google Cloud Vertex AI) |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Unknown |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
eCARTv5 Clinical Deterioration Suite (eCART)AgileMD's eCARTv5 is designed for seamless integration into existing EHR workflows, providing real-time alerts and embedded clinical pathways. This direct integration and focus on minimizing false alarms suggest a highly intuitive user interface and a design aimed at decreasing clinician workload. Google Med-PaLM 2, while powerful, is an API-based large language model, implying a need for custom integration and development to be fully usable within a clinical setting, which could be more complex for end-users.
Clinical Value
eCARTv5 Clinical Deterioration Suite (eCART)eCARTv5 is an FDA-cleared Software as a Medical Device (SaMD) specifically designed for continuous patient risk assessment and prediction of clinical deterioration (death or ICU transfer) in hospitalized adult patients. It has undergone extensive retrospective and prospective validation in large, diverse patient cohorts, demonstrating superior accuracy compared to other early warning scores. Med-PaLM 2, while achieving expert-level performance on medical licensing exams and showing promise in clinical reasoning and multimodal data analysis, is still primarily a large language model and is currently available for limited testing and exploration of use cases, with outputs requiring validation by qualified healthcare professionals.
Pricing & Value
TieBoth tools require contacting the vendor for a tailored quote, making direct pricing comparison difficult. AgileMD's eCARTv5 emphasizes cost efficiency through reduced unnecessary tests and procedures, while Med-PaLM 2's value proposition lies in accelerating diagnostics, enhancing accuracy, and promoting equitable access. Without transparent pricing, it's challenging to definitively declare a winner in terms of overall value.
Enterprise Readiness
eCARTv5 Clinical Deterioration Suite (eCART)AgileMD's eCARTv5 is an FDA-cleared SaMD with established EHR integration, HIPAA compliance, and a SOC-II certification, indicating it is built to rigorous enterprise IT standards. It has been deployed at scale in hundreds of hospitals, demonstrating proven implementation and support for large healthcare systems. Google Med-PaLM 2, while HIPAA compliant and available through Google Cloud, is currently in a limited access phase for select customers, suggesting it is still maturing for widespread enterprise deployment and integration.
Innovation
Google Med-PaLM 2Google Med-PaLM 2 represents a significant innovation as a large language model specifically fine-tuned for healthcare, demonstrating expert-level performance on medical licensing exams and developing multimodal capabilities to interpret various medical data, including images. AgileMD's eCARTv5 is also innovative with its AI-powered clinical deterioration prediction and continuous risk assessment, but Med-PaLM 2's broader AI capabilities and multimodal approach push the boundaries of current healthcare AI applications.
Support & Docs
TieAgileMD offers documentation, in-person, live online, videos, and webinars for training, along with email, phone, chat, FAQ, forum, help desk, knowledge base, tickets, and 24/7 live support. Google Med-PaLM 2, being an API, would likely rely on Google Cloud's extensive documentation and support, but specific healthcare-focused support and documentation for Med-PaLM 2 itself are not as explicitly detailed as AgileMD's offerings. However, as a Google product, it can be assumed that robust technical documentation and support channels are available.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | eCARTv5 Clinical Deterioration Suite (eCART) | Google Med-PaLM 2 |
|---|---|---|
| Name | eCARTv5 Clinical Deterioration Suite (u201ceCARTu201d) | Google Med-PaLM 2 |
| Company | AgileMD | |
| Description | FDA-cleared, AI-powered Software as a Medical Device (SaMD) that integrates with EHRs to continuously assess and predict the risk of clinical deterioration (death or ICU transfer) in hospitalized adult patients, guiding care with embedded clinical pathways. | A large language model specifically built for healthcare, fine-tuned with medical data to assist with clinical decision support, summarization, and medical Q&A. |
| Key Features | AI-powered clinical deterioration prediction, Continuous patient risk assessment (death or ICU transfer), EHR integration with real-time data (up to 97 variables), Embedded clinical pathways for care guidance, Early warning system (alerts hours before critical illness), Risk stratification (eCART score and risk designation), Minimizes false alarms and clinician workload, Reporting and benchmarking capabilities | Expert-level medical question answering (86.5% accuracy on USMLE-style questions), Advanced clinical reasoning capabilities, Comprehensive medical knowledge base, Multi-step problem solving, Medical literature synthesis and analysis, Multimodal data analysis (interprets X-rays, mammograms, CT scans, clinical data, patient histories, genetic information), Evidence-based recommendations, Continuous learning and updates |
| Categories | Clinical Decision Support & Reference, Triage & ER/ICU AI | Clinical Decision Support & Reference, Documentation & Scribing, Medical Education & Training |
| Specialties | Critical Care, Emergency Medicine, Hospital Medicine | Critical Care, Internal Medicine, Radiology |
Videos
Demos, reviews, and walkthroughs featuring eCARTv5 Clinical Deterioration Suite (eCART) and Google Med-PaLM 2.
Frequently Asked Questions
More Comparisons
More matchups featuring eCARTv5 Clinical Deterioration Suite (eCART) or Google Med-PaLM 2
- eCARTv5 Clinical Deterioration Suite (eCART) vs Elsevier
- eCARTv5 Clinical Deterioration Suite (eCART) vs Clair - The AI Clinical Reference Tool
- eCARTv5 Clinical Deterioration Suite (eCART) vs Google Cloud AI (with BAA)
- eCARTv5 Clinical Deterioration Suite (eCART) vs Microsoft Azure AI (with BAA)
- eCARTv5 Clinical Deterioration Suite (eCART) vs Lumiata AI
- eCARTv5 Clinical Deterioration Suite (eCART) vs WellSky SkySense AI
Backers
Who funded each tool's parent company.